Ebdarokimab clinical trials
Also written AK101.
How each study uses ebdarokimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AK101
- 3
Studies by the year they started
5 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses ebdarokimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque PsoriasisCompletedPhase 1/2AkesoNCT04172233Written as AK101
- Clinical Study of AK101 in Subjects With Moderate to Severe Plaque PsoriasisCompletedPhase 2AkesoNCT04173637Written as AK101
- Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With PsoriasisCompletedPhase 3AkesoNCT05509361Written as AK101 injection SC
- A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative ColitisCompletedPhase 1AkesoNCT06281704Written as AK101 IV
- A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With PsoriasisCompletedPhase 3AkesoNCT05120297Written as AK101
Codes
What other systems call ebdarokimab · ClinicalTrials.gg INT017582
- UNII (FDA) PG97J3111AEBDAROKIMABOne source FDA
- NCI Thesaurus C179082EbdarokimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PG97J3111A | EBDAROKIMAB | One source FDA |
| NCI Thesaurus | C179082 | Ebdarokimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.